Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR2E1 | Q9Y466 | 3/20 | 0.59 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.58 |
| ▸ | MAP3K20 | Q9NYL2 | 2/20 | 0.58 |
| ▸ | MAP4K2 | Q12851 | 2/20 | 0.58 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.58 |
| ▸ | EPHB2 | P29323 | 2/20 | 0.57 |
| ▸ | LDLR | P01130 | 3/20 | 0.57 |
| ▸ | KIT | P10721 | 3/20 | 0.57 |
| ▸ | PCSK9 | Q8NBP7 | 3/20 | 0.57 |
| ▸ | ABL1 | P00519 | 10/20 | 0.55 |
| ▸ | BCR | P11274 | 7/20 | 0.55 |
| ▸ | PDGFRB | P09619 | 2/20 | 0.55 |
| ▸ | RAF1 | P04049 | 2/20 | 0.54 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.53 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.53 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.53 |
| ▸ | KDR | P35968 | 1/20 | 0.53 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.53 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.53 |
| ▸ | LCK | P06239 | 2/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30339769 | 1.00 | NR2E1 (0.59) | NR2E1MAPK14MAP3K20MAP4K2MAP3K7 | |
| SCHEMBL24070471 | 0.89 | ABL1 (0.52) | NR2E1MAPK14MAP3K20MAP4K2MAP3K7 | |
| SCHEMBL30211931 | 0.87 | NR2E1 (0.58) | NR2E1MAPK14MAP3K20MAP4K2MAP3K7 | |
| SCHEMBL24070501 | 0.87 | NR2E1 (0.58) | NR2E1MAPK14MAP3K20MAP4K2MAP3K7 | |
| SCHEMBL30211927 | 0.85 | DDR1 (0.65) | NR2E1MAPK14MAP3K20EPHB2LDLR | |
| SCHEMBL24070143 | 0.85 | DDR1 (0.65) | NR2E1MAPK14MAP3K20EPHB2LDLR | |
| SCHEMBL24070155 | 0.82 | ABL1 (0.59) | NR2E1MAPK14MAP3K20MAP4K2MAP3K7 | |
| SCHEMBL25339043 | 0.82 | ABL1 (0.60) | NR2E1MAPK14MAP3K20MAP4K2MAP3K7 | |
| SCHEMBL24071072 | 0.82 | MAPK14 (0.57) | NR2E1MAPK14MAP3K20MAP4K2MAP3K7 | |
| SCHEMBL30211923 | 0.82 | ABL1 (0.59) | NR2E1MAPK14MAP3K20MAP4K2MAP3K7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230227447-A1 | BENZYLAMINE DERIVATIVES AS DDRS INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2023-07-20 | — | — | US | claimed |
| CN-115697485-A | Benzylamine derivatives as DDR inhibitors | 奇斯药制品公司 | 2023-02-03 | — | — | CN | claimed |
| US-20230227447-A1 | BENZYLAMINE DERIVATIVES AS DDRS INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2023-07-20 | — | — | US | disclosed |
| US-20230227447-A1 | BENZYLAMINE DERIVATIVES AS DDRS INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2023-07-20 | — | — | US | disclosed |
| US-20230227447-A1 | BENZYLAMINE DERIVATIVES AS DDRS INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2023-07-20 | — | — | US | disclosed |
| CN-115697485-A | Benzylamine derivatives as DDR inhibitors | 奇斯药制品公司 | 2023-02-03 | — | — | CN | disclosed |
| WO-2021239643-A1 | BENZYLAMINE DERIVATIVES AS DDRS INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2021-12-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230227447-A1 | BENZYLAMINE DERIVATIVES AS DDRS INHIBITORS | DDR2, DDR1, DDRGK1 | NR2E1 134/4885MAPK14 2850/4885MAP3K20 459/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.